Contact Us
Contact Us
Contact Us

Investors

Welcome to our Investor page. Here you will find information on the latest ASX announcements, investor presentations and other shareholder information on Race Oncology.

Race Oncology

Race Oncology is a specialty pharmaceutical company focused on rediscovering and rescuing life-saving drugs that can deliver early commercial milestones. Race Oncology’s first asset is Bisantrene, a small molecule Chemotherapy drug that has been evaluated clinically for Acute Myeloid Leukaemia (AML).

ASX Announcements



DateTitle
17/02/2020Appendix 3GDownload
17/02/2020Race appoints Australian Clinical Program DirectorDownload
03/02/2020Appendix 3X-Prof Borje AnderssonDownload
30/01/2020December 2019 Quarterly ReportDownload
28/01/2020Appendix 3BDownload
28/01/2020Clarification AnnouncementDownload
28/01/2020Prof Borje Andersson appointed as Non-Executive DirectorDownload
14/01/2020Notification of Expiry of Unlisted OptionsDownload
13/01/2020Australian Clinical Trials Manager to replace European RoleDownload
1  2  3  

ASX: RAC

Price

Latest News

Read All Stories

Don't miss important updates

Get the latest news & announcement and stay up-to-date.

© 2019 Race Oncology. Website By Multiplier